Reduction of burden of hemolyzed specimens in a large urban emergency department: A real-world, five years’ experience

In vitro hemolysis may jeopardize patient care because tests results generated using unsuitable specimens may lead to inappropriate patient management. The prevalence of hemolyzed specimens is high in the emergency department (ED). We previously showed that collecting blood by means of a closed system entailing manual aspiration of blood instead of using conventional evacuated systems was effective to cut-down by nearly half the rate of hemolysis. Aim of this real world study was to verify whether longterm replacement of standard evacuated blood collection systems may be really effective to reduce the burden of spurious hemolysis. Starting from May 2014 in the ED of our Hospital vacuum tubes were replaced with S-Monovette serum tubes. We compared data about hemolyzed specimens entered in the two years before the implementation of the new device (i.e., 2012 and 2013) and the two years after introducing SMonovette in manual aspiration mode (i.e. 2015 and 2016). The year 2014 was not considered due to mixed data. The rate of hemolyzed specimens decreased from 4.36% to 3.07% with the use of S-Monovette in manual aspiration mode (Chi squared, 183.8; P<0.001). The likelihood of obtaining hemolyzed specimens was hence reduced by approximately 30% (relative risk, 0.707), with an expected economic saving of approximately 510€/year. The results of this real-world study demonstrate that the use of an alternative closed device encompassing manual aspiration for drawing blood from intravenous catheters may reduce hemolyzed samples by approximately 30%, so representing a valuable perspective for safeguarding patient safety and improving ED efficiency

The use of S-Monovette is effective to reduce the burden of hemolysis in a large urban emergency department

Background: Due to the high prevalence of hemolysis in specimens received from the emergency department (ED), several strategies have been proposed to improve sample quality, but none of these seem effective to overcome the problem. In a preliminary study we showed that the use of S-Monovette blood collection system was effective to lower the risk of hemolysis in venous blood samples collected from intravenous catheters. This study was hence aimed to verify whether the replacement of a conventional vacuum system with S-Monovette may be effective to reduce the burden of hemolysis in the daily practice of a large urban ED. Materials and methods: The study was divided in two observational periods of 4 months each. In the former period, blood was collected from intravenous catheters using BD Vacutainer SST II Plus plastic serum tubes, whereas in the latter period the blood was drawn from intravenous catheters using S-Monovette blood tubes in aspiration mode. Sample hemolysis was automatically assessed in all serum samples by photometrical measurement. Results: The total number of hemolysed serum specimens was 624/14155 (4.41%) in the first phase of the study, and 342/13319 (2.57%) in the second phase of the study (P < 0.001). Conclusion: Results of our study confirm that the introduction of the Sarstedt S-Monovette blood tubes has reduced the hemolysis rate in the emergency department compared to the previously used BD Vacutainer® SST II Plus plastic serum tube

Recovery ability of human adipose stem cells exposed to cobalt nanoparticles: outcome of dissolution

Aim: To demonstrate that cobalt nanoparticles doses are safe for use in humans and to understand the consequences of the particulate effects, which may persist inside the cells. Materials & methods: Human adipose stem cells were used. We evaluated cell recovery by viability test, morphology and ultrastructure using electronic and optical microscopy, while gene expression was assessed utilizing real-time PCR. Results: After exposure, most stem cells recovered their normal function. Co3O4-nanoparticles remained inside the cell for the entirety of the considered time. A slight modification of gene expression was observed in the exposed cells. Conclusion: After exposure to 100 M cobalt nanoparticles, most cells returned to normal function. Nanoparticle toxicity was due to ions released by dissolution as well as from the nanoparticles themselves

Reduction of burden of hemolyzed specimens in a large urban emergency department: A real-world, five years' experience

In vitro hemolysis may jeopardize patient care because tests results generated using unsuitable specimens may lead to inappropriate patient management. The prevalence of hemolyzed specimens is high in the emergency department (ED). We previously showed that collecting blood by means of a closed system entailing manual aspiration of blood instead of using conventional evacuated systems was effective to cut-down by nearly half the rate of hemolysis. Aim of this real world study was to verify whether longterm replacement of standard evacuated blood collection systems may be really effective to reduce the burden of spurious hemolysis. Starting from May 2014 in the ED of our Hospital vacuum tubes were replaced with S-Monovette serum tubes. We compared data about hemolyzed specimens entered in the two years before the implementation of the new device (i.e., 2012 and 2013) and the two years after introducing SMonovette in manual aspiration mode (i.e. 2015 and 2016). The year 2014 was not considered due to mixed data. The rate of hemolyzed specimens decreased from 4.36% to 3.07% with the use of S-Monovette in manual aspiration mode (Chi squared, 183.8; P<0.001). The likelihood of obtaining hemolyzed specimens was hence reduced by approximately 30% (relative risk, 0.707), with an expected economic saving of approximately 510€/year. The results of this real-world study demonstrate that the use of an alternative closed device encompassing manual aspiration for drawing blood from intravenous catheters may reduce hemolyzed samples by approximately 30%, so representing a valuable perspective for safeguarding patient safety and improving ED efficiency

Efficacy of 1998 <i>vs</i> 2006 first-line antiretroviral regimens for HIV infection: an ordinary clinics retrospective investigation

Purpose: The evidence suggesting increased HAART efficacy over time comes from randomized trials or cohort studies. This retrospective multicenter survey aimed to assess the variation over time in the efficacy and tolerability of first-line HAART regimens in unselected patients treated in ordinary clinical settings. Methods: Retrospective analysis of data of all patients starting first-line HAART regimens in 1998 and 2006 at adhering centers in the Italian CISAI group. Results: For the 543 patients included, mean age was 39.1 ± 9.8y in 1998 and 41.0 ± 10.7y in 2006 (p=0.03), with a similar proportion of males. Baseline mean log10 HIV-RNA was 4.56 ± 0.97 copies/mL in 1998 vs 4.91 ± 0.96 copies/mL in 2006 (p&lt;0.001); baseline mean CD4 T-cell counts were 343 ± 314/mm3 in 1998 vs 244 ± 174/mm3 in 2006 (p&lt;0.001). The following outcomes were significantly improved at 48w in 2006: proportion with undetectable HIV-RNA (86.3% vs 58.0%; p&lt;0.001); mean increase in CD4 T-cells count (252 ± 225 vs 173 ± 246; p&lt;0.001); HAART modification (20.1% vs 29.2%; p=0.02); HAART interruption (7.3% vs 14.6%; p=0.01); proportion reporting optimal adherence (92.2% vs 82.7%, p=0.03). No differences were observed in the prevalence of grade 3-4 WHO toxicities (26.4% vs 26.6%; p=0.9). Multivariate logistic regression showed that being treated in 1998 remained an independent predictor of virological failure after several adjustments, including adherence. Conclusions: Our data from patients not included in clinical trials or cohort studies provide an additional line of evidence that the effectiveness of HAART significantly improved in 2006. Treated patients, however, were significantly older and more frequently late HIV presenters in 2006 than in 1998.</br

Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

Background: Social determinants are known to be a driving force of health inequalities, even in high income countries. Aim of our study was to determine if these factors can limit antiretroviral therapy (ART) access, outcome and retention in care of people living with HIV (PLHIV) in Italy. Methods: All ART naïve HIV+ patients (pts) of Italian nationality enrolled in the ICONA Cohort from 2002 to 2016 were included. The association of socio-demographic characteristics (age, sex, risk factor for HIV infection, educational level, occupational status and residency area) with time to: ART initiation (from the first positive anti-HIV test), ART regimen discontinuation, and first HIV-RNA &lt; 50 cp/mL, were evaluated by Cox regression analysis, Kaplan Meier method and log-rank test. Results: A total of 8023 HIV+ pts (82% males, median age at first pos anti-HIV test 36 years, IQR: 29-44) were included: 6214 (77.5%) started ART during the study period. Women, people who inject drugs (PWID) and residents in Southern Italy presented the lowest levels of education and the highest rate of unemployment compared to other groups. Females, pts aged &gt; 50 yrs., unemployed vs employed, and people with lower educational levels presented the lowest CD4 count at ART initiation compared to other groups. The overall median time to ART initiation was 0.6 years (yrs) (IQR 0.1-3.7), with a significant decrease over time [2002-2006 = 3.3 yrs. (0.2-9.4); 2007-2011 = 1.0 yrs. (0.1-3.9); 2012-2016 = 0.2 yrs. (0.1-2.1), p &lt; 0.001]. By multivariate analysis, females (p &lt; 0.01) and PWID (p &lt; 0.001), presented a longer time to ART initiation, while older people (p &lt; 0.001), people with higher educational levels (p &lt; 0.001), unemployed (p = 0.02) and students (p &lt; 0.001) were more likely to initiate ART. Moreover, PWID, unemployed vs stable employed, and pts. with lower educational levels showed a lower 1-year probability of achieving HIV-RNA suppression, while females, older patients, men who have sex with men (MSM), unemployed had higher 1-year risk of first-line ART discontinuation. Conclusions: Despite median time to ART start decreased from 2002 to 2016, socio-demographic factors still contribute to disparities in ART initiation, outcome and durability

Long-term efficacy of boosted and unboosted atazanavir-containing regimens: results from the SCOLTA project

In this study we evaluated the efficacy of boosted and unboosted ATV in different regimens in a cohort of HIV-1 infected patients